Aclaris Therapeutics, Inc. (ACRS)
NASDAQ: ACRS · Real-Time Price · USD
1.560
-0.030 (-1.89%)
Mar 13, 2025, 4:00 PM EST - Market closed
Aclaris Therapeutics Stock Forecast
Stock Price Forecast
The 6 analysts with 12-month price forecasts for Aclaris Therapeutics stock have an average target of 11.67, with a low estimate of 7.00 and a high estimate of 20. The average target predicts an increase of 648.08% from the current stock price of 1.56.
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Aclaris Therapeutics stock from 6 stock analysts is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '24 | Nov '24 | Dec '24 | Jan '25 | Feb '25 | Mar '25 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 2 | 3 | 3 | 3 | 3 |
| Buy | 1 | 2 | 2 | 2 | 2 | 3 |
| Hold | 5 | 2 | 0 | 0 | 0 | 0 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 6 | 6 | 5 | 5 | 5 | 6 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Scotiabank | Scotiabank | Buy Initiates $15 | Buy | Initiates | $15 | +861.54% | Mar 7, 2025 |
| HC Wainwright & Co. | HC Wainwright & Co. | Hold → Strong Buy Upgrades $20 | Hold → Strong Buy | Upgrades | $20 | +1,182.05% | Dec 23, 2024 |
| Leerink Partners | Leerink Partners | Hold → Buy Upgrades $2 → $7 | Hold → Buy | Upgrades | $2 → $7 | +348.72% | Nov 19, 2024 |
| Jefferies | Jefferies | Hold → Strong Buy Upgrades $2 → $7 | Hold → Strong Buy | Upgrades | $2 → $7 | +348.72% | Nov 19, 2024 |
| BTIG | BTIG | Hold → Strong Buy Upgrades $8 | Hold → Strong Buy | Upgrades | $8 | +412.82% | Nov 19, 2024 |
Financial Forecast
Revenue This Year
9.16M
from 18.72M
Decreased by -51.07%
Revenue Next Year
8.42M
from 9.16M
Decreased by -8.05%
EPS This Year
-0.56
from -1.71
EPS Next Year
-0.70
from -0.56
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 20.9M | 22.9M | 25.1M | ||
| Avg | 9.2M | 8.4M | 11.4M | ||
| Low | 2.5M | 2.5M | 2.9M |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | 11.6% | 149.9% | 197.9% | ||
| Avg | -51.1% | -8.0% | 35.0% | ||
| Low | -86.4% | -72.2% | -65.2% |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | -0.16 | -0.51 | -0.78 | ||
| Avg | -0.56 | -0.70 | -0.82 | ||
| Low | -0.96 | -0.91 | -0.85 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 |
|---|---|---|---|---|---|
| High | - | - | - | ||
| Avg | - | - | - | ||
| Low | - | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.